JP2009545309A5 - - Google Patents

Download PDF

Info

Publication number
JP2009545309A5
JP2009545309A5 JP2009522414A JP2009522414A JP2009545309A5 JP 2009545309 A5 JP2009545309 A5 JP 2009545309A5 JP 2009522414 A JP2009522414 A JP 2009522414A JP 2009522414 A JP2009522414 A JP 2009522414A JP 2009545309 A5 JP2009545309 A5 JP 2009545309A5
Authority
JP
Japan
Prior art keywords
cell
mirna
molecule
mammalian
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009522414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009545309A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IE2007/000078 external-priority patent/WO2008015662A1/en
Publication of JP2009545309A publication Critical patent/JP2009545309A/ja
Publication of JP2009545309A5 publication Critical patent/JP2009545309A5/ja
Pending legal-status Critical Current

Links

JP2009522414A 2006-08-04 2007-08-03 組換え型生物学的製剤を製造する方法 Pending JP2009545309A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE20060587 2006-08-04
PCT/IE2007/000078 WO2008015662A1 (en) 2006-08-04 2007-08-03 A method of producing recombinant biological products

Publications (2)

Publication Number Publication Date
JP2009545309A JP2009545309A (ja) 2009-12-24
JP2009545309A5 true JP2009545309A5 (enExample) 2010-09-16

Family

ID=38720408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009522414A Pending JP2009545309A (ja) 2006-08-04 2007-08-03 組換え型生物学的製剤を製造する方法

Country Status (7)

Country Link
US (1) US8476244B2 (enExample)
EP (1) EP2046970B2 (enExample)
JP (1) JP2009545309A (enExample)
CN (1) CN101541972A (enExample)
AU (1) AU2007280004A1 (enExample)
CA (1) CA2658301A1 (enExample)
WO (1) WO2008015662A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2520649A3 (en) * 2007-11-23 2013-02-20 Panagene, Inc. MicroRNA antisense PNAs, compositions comprising the same, and methods for using and evaluating the same
MX374424B (es) 2012-05-21 2025-03-06 Genentech Inc Metodos para mejorar la seguridad del transporte de la barrera hematoencefalica.
EP3536789A1 (en) * 2012-06-06 2019-09-11 Boehringer Ingelheim International GmbH Cell engineering using rnas
ES2743506T3 (es) 2013-03-14 2020-02-19 Medimmune Llc Producción de polipéptidos recombinantes
WO2014204405A1 (en) * 2013-06-18 2014-12-24 Agency For Science, Technology And Research Method for modulating recombinant protein production
CN105849265B (zh) * 2013-08-06 2021-03-26 英国龙沙生物医药股份有限公司 用于产生供生产重组蛋白的哺乳动物生产细胞的物品和方法
PL3063278T3 (pl) * 2013-11-01 2018-08-31 Sementis Limited Wytwarzanie wektora wirusowego
DE102017128356B4 (de) 2017-11-30 2024-10-10 TRUMPF Laser SE Scanspiegel und Scanspiegel-Einheit für ein Laser-Scansystem

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000006549A (ko) * 1998-06-30 2000-01-25 윤재승 생체내혈소판증식효능이향상된신규한트롬보포이에틴유도체
EP2530157B1 (en) * 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
EP1791954A1 (en) * 2004-09-07 2007-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
EP2377559A1 (en) 2005-06-03 2011-10-19 Southern Adelaide Health Service - Flinders Medical Centre Targeting cells with altered microRNA expression

Similar Documents

Publication Publication Date Title
CN108753836B (zh) 一种利用rna干扰机制的基因调控或编辑系统
NO20062683L (no) P EF-TU- ekspresjonsenheter
Olive et al. Outside the coding genome, mammalian microRNAs confer structural and functional complexity
CN104651398A (zh) 利用CRISPR-Cas9特异敲出microRNA基因家族的方法
DE502004000547D1 (de) Verfahren zur fermentativen Herstellung von L-Methionin
MX2013006018A (es) Produccion de polimeros peine mediante esterificacion.
JP2016513478A5 (enExample)
MY166543A (en) A microorganism for methionine production with enhanced glucose import
CN106032532A (zh) 一种小激活rna及其制备方法和应用
NZ596432A (en) Reverse genetics using non-endogenous pol i promoters
CN109097395A (zh) 一种人类环状rna过表达载体框架、过表达载体及其制备方法
CN107058360A (zh) 一种基于快速克隆技术的环状rna表达载体构建方法及其应用
EP2046970B2 (en) A method of producing recombinant biological products
Li et al. MiR-122 targets the vanin 1 gene to regulate its expression in chickens
Wang et al. Engineering Escherichia coli for autoinducible production of n-butanol
NZ599479A (en) Improved reverse genetics methods for virus rescue
Liu et al. Identification of a novel small-molecule inhibitor of miR-29b attenuates muscle atrophy
DK1751292T3 (da) Fremgangsmåde til fremstilling af ravsyre ud fra rå hydrolysater
Shan et al. A quick and efficient approach for gene silencing by using triple putative microRNA-based short hairpin RNAs
ATE537159T1 (de) Verfahren zur herstellung von glycidylestern
CN103397034A (zh) miRNA-19a作为哺乳动物宿主细胞增殖调控靶标的应用
WO2018165929A1 (zh) 一种双miRNA抑制表达载体及其构建方法和应用
Sadahiro Direct Cardiac Reprogramming―Converting Cardiac Fibroblasts to Cardiomyocytes―
WO2017214948A1 (zh) 一种敲低人 miRNA-148a 表达的慢病毒载体的构建及其应用
ATE416156T1 (de) Verfahren zur herstellung von acetessigsäurearylamiden